Amyloid-β: The seeds of darkness

International Journal of Biochemistry and Cell Biology

Volumn 43, Issue 9, 2011, Pages 1247-1251

  Fodero Tavoletti, Michelle T ^a   Villemagne, Victor L ^b,c   Rowe, Christopher C ^b   Masters, Colin L ^c   Barnham, Kevin J ^a,c   Cappai, Roberto ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Alzheimer's disease; A ; A oligomers; Dementia; Pathology

Indexed keywords

AMYLOID BETA PROTEIN; BAPINEUZUMAB; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; GENETIC ASSOCIATION; HUMAN; IMMUNOTHERAPY; NERVE DEGENERATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN STRUCTURE;

EID: 79960905062     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2011.05.001     Document Type: Short Survey

References (33)

1. O.N. Antzutkin, R.D. Leapman, J.J. Balbach, and R. Tycko Supramolecular structural constraints on Alzheimer's beta-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance Biochemistry 41 51 2002 15436 15450 (Pubitemid 36008156)
2. H. Braak, and E. Braak Neuropathological stageing of Alzheimer-related changes Acta Neuropathol (Berl) 82 4 1991 239 259
3. M.A. Chishti, D.S. Yang, C. Janus, A.L. Phinney, P. Horne, and J. Pearson Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695 J Biol Chem 276 24 2001 21562 21570 (Pubitemid 37413154)
4. E.H. Corder, A.M. Saunders, N.J. Risch, W.J. Strittmatter, D.E. Schmechel, and P.C. Gaskell Jr. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease Nat Genet 7 2 1994 180 184 (Pubitemid 24174658)
5. B.J. Cummings, and C.W. Cotman Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity Lancet 346 8989 1995 1524 1528 (Pubitemid 3006327)
6. 2+ coordination of Alzheimer's disease amyloid-beta peptide - relevance to N-terminally truncated forms J Am Chem Soc 131 25 2009 8760 8761
7. M. Gatz, C.A. Reynolds, L. Fratiglioni, B. Johansson, J.A. Mortimer, and S. Berg Role of genes and environments for explaining Alzheimer disease Arch Gen Psychiatry 63 2 2006 168 174 (Pubitemid 43213878)
8. C. Haass, and D.J. Selkoe Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide Nat Rev Mol Cell Biol 8 2 2007 101 112 (Pubitemid 46432529)
9. O. Hansson, H. Zetterberg, P. Buchhave, U. Andreasson, E. Londos, and L. Minthon Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment Dement Geriatr Cogn Disord 23 5 2007 316 320 (Pubitemid 46631938)
10. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 5580 2002 353 356 (Pubitemid 34790756)
11. T. Iwatsubo, A. Odaka, N. Suzuki, H. Mizusawa, N. Nukina, and Y. Ihara Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43) Neuron 13 1 1994 45 53
12. S. Kumar-Singh, J. Theuns, B. Van Broeck, D. Pirici, K. Vennekens, and E. Corsmit Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40 Hum Mutat 27 7 2006 686 695
13. M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, and M. Liosatos Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins Proc Natl Acad Sci U S A 95 11 1998 6448 6453
14. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, and J. Harrison Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol 7 9 2008 779 786
15. C.A. Lemere, J.K. Blusztajn, H. Yamaguchi, T. Wisniewski, T.C. Saido, and D.J. Selkoe Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation Neurobiol Dis 3 1 1996 16 32
16. C.L. Masters, R. Cappai, K.J. Barnham, and V.L. Villemagne Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics J Neurochem 97 6 2006 1700 1725 (Pubitemid 43873662)
17. K.G. Mawuenyega, W. Sigurdson, V. Ovod, L. Munsell, T. Kasten, and J.C. Morris Decreased clearance of CNS beta-amyloid in Alzheimer's disease Science 330 6012 2010 1774
18. J. McLaurin, and P.E. Fraser Effect of amino-acid substitutions on Alzheimer's amyloid-beta peptide-glycosaminoglycan interactions Eur J Biochem 267 2000 6353 6361
19. C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, and K. Beyreuther Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease Ann Neurol 46 6 1999 860 866
20. R.L. Patton, W.M. Kalback, C.L. Esh, T.A. Kokjohn, G.D. Van Vickle, and D.C. Luehrs Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis Am J Pathol 169 3 2006 1048 1063 (Pubitemid 44411966)
21. R.C. Petersen, R.O. Roberts, D.S. Knopman, B.F. Boeve, Y.E. Geda, and R.J. Ivnik Mild cognitive impairment: ten years later Arch Neurol 66 12 2009 1447 1455
22. M. Pride, P. Seubert, M. Grundman, M. Hagen, J. Eldridge, and R.S. Black Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis Neurodegener Dis 5 3-4 2008 194 196 (Pubitemid 351347848)
23. J.O. Rinne, D.J. Brooks, M.N. Rossor, N.C. Fox, R. Bullock, and W.E. Klunk 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol 9 4 2010 363 372
24. J.S. Ross, and B.P. Imbimbo Are gamma-secretase inhibitors detrimental for Alzheimer's disease patients? J Alzheimers Dis 22 2 2010 401 404
25. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, and M. Raskind A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 24 2009 2061 2070
26. L.S. Schneider, P.S. Insel, and M.W. Weiner Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative Arch Neurol 68 1 2011 58 66
27. M. Sjogren, H. Vanderstichele, H. Agren, O. Zachrisson, M. Edsbagge, and C. Wikkelso Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values Clin Chem 47 10 2001 1776 1781 (Pubitemid 32881189)
28. Z. Stozicka, N. Zilka, and M. Novak Risk and protective factors for sporadic Alzheimer's disease Acta Virol 51 4 2007 205 222
29. V.N. Uversky Mysterious oligomerization of the amyloidogenic proteins FEBS J 277 14 2010 2940 2953
30. V.L. Villemagne, K.A. Perez, K.E. Pike, W.M. Kok, C.C. Rowe, and A.R. White Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease J Neurosci 30 18 2010 6315 6322
31. V.L. Villemagne, K.E. Pike, D. Darby, P. Maruff, G. Savage, and S. Ng Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease Neuropsychologia 46 6 2008 1688 1697
32. G.L. Wenk Neuropathologic changes in Alzheimer's disease J Clin Psychiatry 64 Suppl. 9 2003 7 10 (Pubitemid 37040372)
33. O. Wirths, T. Bethge, A. Marcello, A. Harmeier, S. Jawhar, and P.J. Lucassen Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases J Neural Transm 117 1 2010 85 96